Anti-angiogenic therapy follow-up in mice brain glioma model with P04000, a new molecular imaging avb3-nanoemulsion of iron oxide.
VIOLAS Xavier 1 , ROBERT Philippe 2 , NAIN DIT DUCRET Martine 2 , ROBIC Caroline 2 , BALLET Sebastien 2 , and COROT Claire 2
Guerbet, Aulnay sous bois, France,
A new iron oxide nanoparticle based USPIO (P04000) is
evaluated in terms of specificity and capacity to
monitor antiangiogenic treatment in a brain tumor model
in mice. The high affinity rgd vectored contrast agent
who targets avb3 allows, with a basic Multi Gradient
Echo sequence, to specifically enhance the tumor 2 hours
post injection. The uptake of this agent is reduced to
zero in the bevacizumab treated group before the tumor
regression. This MR contrast agent is able to early
demonstrate the effect of anti-angiogenic therapy with
feasible MRI sequence and data post processing in
This abstract and the presentation materials are available to members only;
a login is required.